Genmab A/S: Delårsrapport for første kvartal af 2026
7/5 17:16
Genmab’s revenue for Q1 2026 rose 25% to $896 million, driven by increased royalties from DARZALEX and Kesimpta. Operating costs increased to $716 million, resulting in an operating profit of $180 million. The company maintains its full-year revenue forecast of $4.1-4.4 billion. Net profit for the quarter was $53 million, down from $195 million in […]...